John Capek talks about ways we can improve not only the predictability but also the potential success for technologies in order to improve the overall delivery of healthcare over the next decade.
He considers important industry trends, such as demographic and globalization, which affect Abbott is considering technologies as they are brought into the market.
He presents key statistics on critical data points such as the demographic for healthcare spending, on Asia emerging as a market for the healthcare sector, and the role of diabetes treatment in healthcare systems.
In talking about the evolution of the healthcare industry, he cites an example of the transition in modes of therapy in the field of Interventional Cardiology. In the first 25 years, the predominant mode of therapy in Interventional Cardiology was mechanical, whether that be with Balloon Angioplasty or atherectomy devices. Now, in the recent years, he continues, we are making the transition into molecular cardiology solutions using genetic modifiers, drug eluting stents, protein deliverers and such genetic engineering approaches. This is having a significant impact on the market place.
He argues that a strong driver for growth in the medical devices segment is the integration of four major categories of technologies, namely, IT/Health Services, Pharma, Genetics, and devices.
The Executive Vice President of Medical Devices puts into context the impact of healthcare reform on the delivery of technologies.
John Capek, Ph.D., is Executive Vice President, Medical Devices. Previously, he served as Senior Vice President, Abbott Vascular, heading up Abbott's global vascular business.
Before joining Abbott, Mr. Capek served in various management roles at Guidant Corporation, including president, Guidant Vascular Intervention and vice president and general manager of Bioabsorbable Vascular Solutions. He also served as vice president and general manager of Guidant Germany and vice president, marketing, Guidant Cardiac Rhythm Management Group. Before joining Guidant, Mr. Capek was manager of New Product Technology at Eli Lilly & Company.
He has a bachelor's degree in biomedical engineering, a master's degree in biomedical engineering, a master's degree in electrical engineering, a Ph.D. in biomedical engineering and a master's degree in business administration from Rensselaer Polytechnic Institute.
Resources
This free podcast is from our The Future of Health Care series.
For The Conversations Network:
Photo: GSB 2011 Healthcare Summit